Spondyloarthritis & psoriatic arthritis
FIB-4 as an effective screening tool in psoriatic arthritis patients at high-risk for liver disease: a cross-sectional study using FibroScan
Authors' conclusion
CSLD is common in high-risk PsA patients and strongly associated with metabolic risk factors. FIB-4 ≥1.3 had high negative predictive value, supporting its use as a first-line screening tool.
Study context
- Population
- PsA patients referred for liver assessment due to suspected clinically significant liver disease (CSLD) secondary to MASLDmedian age 51.0 years
- Participants
- 89 patients
- Outcome
- Performance of non-invasive screening tools (FIB-4, Enhanced Liver Fibrosis (ELF), BARD) in identifying MASLD causing CSLD (liver stiffness measurement (LSM) >10 kPa on FibroScan and/or US and/or biopsy showing steatosis/fibrosis/cirrhosis secondary to MASLD)
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
CSLD prevalence
CSLD identified
55/89 patients
61.8%
Observational data: associations, not effects.
Further findings
| Outcome | Values |
|---|---|
| Diagnostic performance of FIB-4 ≥1.3 for CSLD | FIB-4 ≥1.3 sensitivity 47.8% · specificity 77.2% · PPV 6.1% · NPV 98.0% |
Factors independently associated with CSLD (multivariable regression)
- Hypertension, BMI >30 kg/m² and FIB-4 ≥1.3 remained independently associated
- MTX exposure not associated with CSLD
Cardiometabolic comorbidities
- ≥1 metabolic risk factor
- 96.6%
- Obese
- 69.7%
Original publication
FIB-4 as an effective screening tool in psoriatic arthritis patients at high-risk for liver disease: a cross-sectional study using FibroScan. Rheumatology (Oxford). Published 2 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →